相似文献
1
Controlled ocular delivery of acyclovir through rate controlling ocular insert of Eudragit: a technical note.
AAPS PharmSciTech. 2008;9(1):169-73. doi: 10.1208/s12249-008-9032-1. Epub 2008 Jan 25.
2
Eudragit microparticles as a possible tool for ophthalmic administration of acyclovir.
J Microencapsul. 2007 Aug;24(5):445-56. doi: 10.1080/02652040701374889.
3
Flexible coils with a drug-releasing hydrophilic coating: a new platform for controlled delivery of drugs to the eye?
Biomed Mater Eng. 2004;14(4):383-93.
4
Floating properties and release characteristics of hollow microspheres of acyclovir.
Drug Deliv. 2008 Jun;15(5):331-41. doi: 10.1080/10717540802035335.
5
Bioadhesive microspheres for ophthalmic administration of acyclovir.
J Pharm Pharmacol. 1997 Aug;49(8):737-42. doi: 10.1111/j.2042-7158.1997.tb06103.x.
6
Controlled release polymeric ocular delivery of acyclovir.
Pharm Dev Technol. 2010 Jul-Aug;15(4):369-78. doi: 10.3109/10837450903262017.
7
In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery.
Int J Biol Macromol. 2014 Jun;67:478-82. doi: 10.1016/j.ijbiomac.2014.04.019. Epub 2014 Apr 19.
8
Future of contact lens usage.
Cont Lens Anterior Eye. 2013 Aug;36(4):155. doi: 10.1016/j.clae.2013.05.001.
9
Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review.
Cont Lens Anterior Eye. 2008 Apr;31(2):57-64. doi: 10.1016/j.clae.2007.09.002. Epub 2007 Oct 25.
10
Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments.
Int J Pharm. 2015 Sep 30;493(1-2):412-25. doi: 10.1016/j.ijpharm.2015.07.066. Epub 2015 Jul 29.
引用本文的文献
1
Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers.
Viruses. 2023 Feb 28;15(3):647. doi: 10.3390/v15030647.
2
Ophthalmic drug dosage forms: characterisation and research methods.
ScientificWorldJournal. 2014 Mar 18;2014:861904. doi: 10.1155/2014/861904. eCollection 2014.
3
Ocular insert for sustained delivery of gatifloxacin sesquihydrate: Preparation and evaluations.
Int J Pharm Investig. 2012 Apr;2(2):70-7. doi: 10.4103/2230-973X.100040.
本文引用的文献
1
Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability.
Pharm Res. 2003 Apr;20(4):584-90. doi: 10.1023/a:1023290514575.
2
A study of release mechanisms of different ophthalmic drugs from erodible ocular inserts based on poly(ethylene oxide).
Eur J Pharm Biopharm. 2002 Sep;54(2):193-9. doi: 10.1016/s0939-6411(02)00086-3.
3
Controlled release and ocular absorption of tilisolol utilizing ophthalmic insert-incorporated lipophilic prodrugs.
J Control Release. 2001 Oct 19;76(3):255-63. doi: 10.1016/s0168-3659(01)00441-2.
4
Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.
J Pharm Sci. 2001 Mar;90(3):288-97. doi: 10.1002/1520-6017(200103)90:3<288::aid-jps4>3.0.co;2-5.
5
Ocular delivery systems of pefloxacin mesylate.
Pharmazie. 1999 Jan;54(1):55-8.
6
Bioadhesive microspheres for ophthalmic administration of acyclovir.
J Pharm Pharmacol. 1997 Aug;49(8):737-42. doi: 10.1111/j.2042-7158.1997.tb06103.x.
7
Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy.
J Ocul Pharmacol. 1994 Summer;10(2):439-51. doi: 10.1089/jop.1994.10.439.
8
Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.
Drugs. 1994 Jan;47(1):153-205. doi: 10.2165/00003495-199447010-00009.
9
Ocular drug delivery. Pharmacokinetic considerations.
Clin Pharmacokinet. 1990 Apr;18(4):255-69. doi: 10.2165/00003088-199018040-00001.
Zotero 插件